Pfizer will price its Covid antiviral drug, Paxlovid, at $1,390 for a five-day course when it becomes available on the commercial market. This price is more than double what the federal government paid for the drug. Concerns have been raised about limited access for vulnerable patients, but health insurance plans are expected to cover a significant portion of the cost. Pfizer plans to work with payers to lower copays and subsidize copays for commercially insured individuals until 2028. As a result, Pfizer has revised its revenue expectations for 2023, predicting lower sales due to the return of emergency use doses and lower demand for its COVID-19 products.